{"protocolSection":{"identificationModule":{"nctId":"NCT00520676","orgStudyIdInfo":{"id":"11626"},"secondaryIdInfos":[{"id":"H3E-CR-S380","type":"OTHER","domain":"Eli Lilly and Company"}],"organization":{"fullName":"Eli Lilly and Company","class":"INDUSTRY"},"briefTitle":"Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer","officialTitle":"A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2011-08","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2007-10"},"primaryCompletionDateStruct":{"date":"2010-07","type":"ACTUAL"},"completionDateStruct":{"date":"2010-07","type":"ACTUAL"},"studyFirstSubmitDate":"2007-08-22","studyFirstSubmitQcDate":"2007-08-22","studyFirstPostDateStruct":{"date":"2007-08-24","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-06-17","resultsFirstSubmitQcDate":"2011-06-17","resultsFirstPostDateStruct":{"date":"2011-07-18","type":"ESTIMATED"},"lastUpdateSubmitDate":"2011-08-08","lastUpdatePostDateStruct":{"date":"2011-08-10","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"oldNameTitle":"Chief Medical Officer","oldOrganization":"Eli Lilly and Company"},"leadSponsor":{"name":"Eli Lilly and Company","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":260,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"pemetrexed plus carboplatin","type":"EXPERIMENTAL","description":"Drug: pemetrexed 500 milligrams per square meter (mg/m\\^2), intravenous (IV), every (q) 21 days x 6 cycles maximum\n\nDrug: carboplatin Area Under the Curve (AUC) 5 milligram\\*minute/milliLiter (mg\\*min/mL), IV, q 21 days x 6 cycles maximum","interventionNames":["Drug: pemetrexed","Drug: carboplatin"]},{"label":"docetaxel plus carboplatin","type":"ACTIVE_COMPARATOR","description":"Drug: docetaxel 75 mg/m\\^2, IV, q 21 days x 6 cycles maximum\n\nDrug: carboplatin AUC 5 mg\\*min/mL, IV, q 21 days x 6 cycles maximum","interventionNames":["Drug: docetaxel","Drug: carboplatin"]}],"interventions":[{"type":"DRUG","name":"pemetrexed","description":"500 mg/m\\^2, IV, q 21 days x 6 cycles maximum","armGroupLabels":["pemetrexed plus carboplatin"],"otherNames":["LY231514","Alimta"]},{"type":"DRUG","name":"docetaxel","description":"75 mg/m\\^2, IV, q 21 days x 6 cycles maximum","armGroupLabels":["docetaxel plus carboplatin"]},{"type":"DRUG","name":"carboplatin","description":"AUC 5 mg\\*min/mL, IV, q 21 days x 6 cycles maximum","armGroupLabels":["docetaxel plus carboplatin","pemetrexed plus carboplatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Survival Without Grade 3 or 4 Toxicity","description":"Defined as the time from date of randomization to first date of a Grade 3 or 4 treatment-emergent adverse event (TEAE; as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \\[CTCAE\\], version 3.0) or death due to any cause. Grade 3 TEAE: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4 TEAE: Life-threatening consequences; urgent intervention indicated.\n\nParticipants who were alive without experiencing Grade 3 or 4 toxicity were censored at the date of last contact.","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months)."}],"secondaryOutcomes":[{"measure":"Overall Survival (OS)","description":"OS is the duration from enrollment to death. For participants who are alive, OS is censored at the last contact.","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months)."},{"measure":"Progression-free Survival (PFS)","description":"Defined as the time from date of first dose to the first observation of disease progression (PD), or death due to any cause.","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months)."},{"measure":"Percentage of Participants With Tumor Response (Response Rate)","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes not meeting above criteria. Response rate (%)=Number of participants with CR+PR/Number of participants analyzed \\*100. Disease Control rate=Number of participants with SD+PR+CR/Number of participants analyzed \\*100.","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months)."},{"measure":"Survival Without Clinically Important Grade 3 or 4 Toxicity","description":"Survival without Grade 3 or 4 toxicity is the time from date of randomization to the first date of the following clinically important Grade 3 or 4 TEAEs graded by the Common Terminology Criteria for Adverse Events \\[CTCAE\\], version 3.0: neutropenia (lasting \\>5 days), febrile neutropenia, documented infections related to neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events; or death due to any cause. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored for this analysis at the date of last contact.","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months)."},{"measure":"Survival Without Grade 4 Toxicity","description":"Survival without Grade 4 toxicity is the time from the date of randomization to the first date of a Grade 4 TEAE or death due to any cause. Participants who are alive without experiencing Grade 4 toxicity will be censored for this analysis at the date of last contact.","timeFrame":"Baseline to until 218 events (defined as death or Grade 4 toxicity) have been observed (up to 33.3 months)."},{"measure":"Number of Participants With Adverse Events (AEs)","description":"Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months)."}],"otherOutcomes":[{"measure":"Duration of Response","description":"The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of longest diameter of target lesions.","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months)."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient with locally advanced or metastatic (Stage IIIB/IV) NCSLC with no prior chemotherapy for advanced disease or molecular target treatment\n* Easter Cooperative Oncology Group (ECOG) performance status 0 to 2\n* Estimated life expectancy of at least 8 weeks\n\nExclusion Criteria:\n\n* Known or suspected brain metastases\n* Concurrent administration of any other tumor therapy\n* Serious concomitant disorders\n* Pregnancy or breast feeding\n* Inability or unwillingness to take folic acid or vitamin B12 supplementation","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)","affiliation":"Eli Lilly and Company","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ballarat","state":"Victoria","zip":"3350","country":"Australia","geoPoint":{"lat":-37.56622,"lon":143.84957}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Frankston","state":"Victoria","zip":"3199","country":"Australia","geoPoint":{"lat":-38.14458,"lon":145.12291}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Wendouree","state":"Victoria","zip":"3355","country":"Australia","geoPoint":{"lat":-37.53078,"lon":143.82838}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Bunbury","state":"Western Australia","zip":"6230","country":"Australia","geoPoint":{"lat":-33.32711,"lon":115.64137}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Barretos","zip":"14784700","country":"Brazil","geoPoint":{"lat":-20.55722,"lon":-48.56778}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Goiânia","zip":"74075040","country":"Brazil","geoPoint":{"lat":-16.67861,"lon":-49.25389}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Santo André","zip":"09060-020","country":"Brazil","geoPoint":{"lat":-23.66389,"lon":-46.53833}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"São Paulo","zip":"01224 010","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Beijing","zip":"100036","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Nanjing","zip":"210002","country":"China","geoPoint":{"lat":32.06167,"lon":118.77778}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Shanghai","zip":"200032","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ciudad Obregón","zip":"85100","country":"Mexico","geoPoint":{"lat":27.48642,"lon":-109.94079}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Durango","zip":"34208","country":"Mexico","geoPoint":{"lat":24.02032,"lon":-104.65756}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mexicali","zip":"21000","country":"Mexico","geoPoint":{"lat":32.62781,"lon":-115.45446}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Mexico City","zip":"11640","country":"Mexico","geoPoint":{"lat":19.42847,"lon":-99.12766}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Seoul","zip":"120-752","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Suwon","zip":"442-723","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Ulsan","zip":"682-714","country":"South Korea","geoPoint":{"lat":35.53722,"lon":129.31667}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taichung","zip":"404","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.","city":"Taoyuan District","zip":"333","country":"Taiwan","geoPoint":{"lat":24.9896,"lon":121.3187}}]},"referencesModule":{"references":[{"pmid":"37922432","type":"DERIVED","citation":"Loureiro H, Kolben TM, Kiermaier A, Ruttinger D, Ahmidi N, Becker T, Bauer-Mehren A. Correlation Between Early Trends of a Prognostic Biomarker and Overall Survival in Non-Small-Cell Lung Cancer Clinical Trials. JCO Clin Cancer Inform. 2023 Sep;7:e2300062. doi: 10.1200/CCI.23.00062."},{"pmid":"24277116","type":"DERIVED","citation":"Pereira JR, Cheng R, Orlando M, Kim JH, Barraclough H. Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer. Drugs R D. 2013 Dec;13(4):289-96. doi: 10.1007/s40268-013-0032-6."}],"seeAlsoLinks":[{"label":"Lilly Clinical Trial Registry","url":"http://www.lillytrials.com"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Analyses were conducted on the qualified intent-to-treat population (Q-ITT) unless otherwise specified. This population includes all data from all randomized participants, with nonsquamous histology, receiving at least 1 dose of the study drug according to the treatment the participants were assigned.","groups":[{"id":"FG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"FG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"128"},{"groupId":"FG001","numSubjects":"132"}]},{"type":"Received at Least 1 Dose of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"127"}]},{"type":"Qualified Intent-to-treat (Q-ITT)","achievements":[{"groupId":"FG000","numSubjects":"106"},{"groupId":"FG001","numSubjects":"105"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"29"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"101"},{"groupId":"FG001","numSubjects":"103"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"84"},{"groupId":"FG001","numSubjects":"81"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"10"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"11"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"BG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"106"},{"groupId":"BG001","value":"105"},{"groupId":"BG002","value":"211"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.6","spread":"10.0"},{"groupId":"BG001","value":"59.2","spread":"10.7"},{"groupId":"BG002","value":"59.4","spread":"10.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"97"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"64"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"114"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Taiwan","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"12"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"39"}]}]},{"title":"Brazil","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"60"}]}]},{"title":"Australia","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"24"}]}]},{"title":"China","categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"37"}]}]},{"title":"Korea, Republic of","categories":[{"measurements":[{"groupId":"BG000","value":"21"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"39"}]}]}]},{"title":"Smoking Status","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Never Smoking","categories":[{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"75"}]}]},{"title":"Ever Smoking but Quit","categories":[{"measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"114"}]}]},{"title":"Currently Smoking","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"22"}]}]}]},{"title":"Histology","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Adenocarcinoma, lung","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"21"}]}]},{"title":"Adenocarcinoma, not otherwise specified","categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"160"}]}]},{"title":"Large cell carcinoma, lung","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"19"}]}]},{"title":"Carcinoma, lung","categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Survival Without Grade 3 or 4 Toxicity","description":"Defined as the time from date of randomization to first date of a Grade 3 or 4 treatment-emergent adverse event (TEAE; as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events \\[CTCAE\\], version 3.0) or death due to any cause. Grade 3 TEAE: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated. Grade 4 TEAE: Life-threatening consequences; urgent intervention indicated.\n\nParticipants who were alive without experiencing Grade 3 or 4 toxicity were censored at the date of last contact.","populationDescription":"Analysis was performed on protocol-qualified, intent-to-treat (Q-ITT) population. This population includes all data from all randomized participants, with nonsquamous histology, receiving at least 1 dose of the study drug according to the treatment the participants were assigned.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).","groups":[{"id":"OG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"OG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","lowerLimit":"2.1","upperLimit":"3.7"},{"groupId":"OG001","value":"0.7","lowerLimit":"0.5","upperLimit":"1.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"The comparison was conducted at a 1-sided significance level of 0.05.","statisticalMethod":"Log Rank","statisticalComment":"Note that the 2-sided p-value for log rank is reported, which is \\<0.001, hence 1-sided p-value is \\<0.001.","paramType":"Hazard Ratio (HR)","paramValue":"0.45","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.34","ciUpperLimit":"0.60","estimateComment":"Cox regression model is used for HR estimate."}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is the duration from enrollment to death. For participants who are alive, OS is censored at the last contact.","populationDescription":"Analysis was performed on protocol-qualified, intent-to-treat (Q-ITT) population. This population includes all data from all randomized participants, with nonsquamous histology, receiving at least 1 dose of the study drug according to the treatment the participants were assigned.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).","groups":[{"id":"OG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"OG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.9","lowerLimit":"12.2","upperLimit":"19.0"},{"groupId":"OG001","value":"14.7","lowerLimit":"10.8","upperLimit":"19.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.934","pValueComment":"The comparison was conducted at a 2-sided significance level of 0.05.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.01","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"1.42","estimateComment":"Cox regression model is used for hazard ratio (HR) estimate."}]},{"type":"SECONDARY","title":"Progression-free Survival (PFS)","description":"Defined as the time from date of first dose to the first observation of disease progression (PD), or death due to any cause.","populationDescription":"Analysis was performed on protocol-qualified, intent-to-treat (Q-ITT) population. This set includes all data from all randomized participants, with nonsquamous histology, receiving at least 1 dose of the study drug according to the treatment the participants were assigned.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).","groups":[{"id":"OG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"OG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","lowerLimit":"4.8","upperLimit":"6.4"},{"groupId":"OG001","value":"6.0","lowerLimit":"4.8","upperLimit":"6.6"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.800","pValueComment":"The comparison was conducted at a 2-sided significance level of 0.05.","statisticalMethod":"Log Rank","statisticalComment":"Cox regression model is used for hazard ratio (HR) estimate.","paramType":"Hazard Ratio (HR)","paramValue":"0.96","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.72","ciUpperLimit":"1.29"}]},{"type":"SECONDARY","title":"Percentage of Participants With Tumor Response (Response Rate)","description":"Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=at least a 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=at least a 20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes not meeting above criteria. Response rate (%)=Number of participants with CR+PR/Number of participants analyzed \\*100. Disease Control rate=Number of participants with SD+PR+CR/Number of participants analyzed \\*100.","populationDescription":"Analysis was performed on tumour response-qualified population. This population includes all participants with locally advanced or metastatic non-small cell lung cancer (NSCLC), non-squamous histology with measurable disease as defined by RECIST (Version 1.0), who received at least 1 dose of pemetrexed, docetaxel, or carboplatin.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).","groups":[{"id":"OG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"OG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"104"}]}],"classes":[{"title":"Tumor Response Rate","categories":[{"measurements":[{"groupId":"OG000","value":"34.0","lowerLimit":"25.0","upperLimit":"43.8"},{"groupId":"OG001","value":"23.1","lowerLimit":"15.4","upperLimit":"32.4"}]}]},{"title":"Disease Control Rate","categories":[{"measurements":[{"groupId":"OG000","value":"74.5","lowerLimit":"65.1","upperLimit":"82.5"},{"groupId":"OG001","value":"64.4","lowerLimit":"54.4","upperLimit":"73.6"}]}]},{"title":"Complete Response","categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"0.0","upperLimit":"5.1"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"3.5"}]}]},{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"33.0","lowerLimit":"24.2","upperLimit":"42.8"},{"groupId":"OG001","value":"23.1","lowerLimit":"15.4","upperLimit":"32.4"}]}]},{"title":"Stable Disease","categories":[{"measurements":[{"groupId":"OG000","value":"40.6","lowerLimit":"31.1","upperLimit":"50.5"},{"groupId":"OG001","value":"41.3","lowerLimit":"31.8","upperLimit":"51.4"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"9.6","upperLimit":"24.4"},{"groupId":"OG001","value":"17.3","lowerLimit":"10.6","upperLimit":"26.0"}]}]},{"title":"Unknown","categories":[{"measurements":[{"groupId":"OG000","value":"9.4","lowerLimit":"4.6","upperLimit":"16.7"},{"groupId":"OG001","value":"18.3","lowerLimit":"11.4","upperLimit":"27.1"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.081","pValueComment":"The comparison of tumor response rates was conducted at a 2-sided significance level of 0.05.","statisticalMethod":"Fisher Exact","statisticalComment":"Tumor response rate= # participants with a confirmed best response of CR or PR / # of participants who qualify for the analysis population.","paramType":"Odds Ratio (OR)","paramValue":"1.71","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.93","ciUpperLimit":"3.15","estimateComment":"Logistic regression model is used for odds ratio (OR) estimate."}]},{"type":"OTHER_PRE_SPECIFIED","title":"Duration of Response","description":"The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR=disappearance of all target lesions; PR=at least a 30% decrease in sum of longest diameter of target lesions.","populationDescription":"Analysis was performed on tumour response qualified population. This population includes all participants with locally advanced or metastatic non-small cell lung cancer (NSCLC), non-squamous histology with measurable disease as defined by RECIST (Version 1.0), who received at least 1 dose of pemetrexed, docetaxel, or carboplatin.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).","groups":[{"id":"OG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"OG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"104"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","lowerLimit":"4.0","upperLimit":"8.1"},{"groupId":"OG001","value":"5.4","lowerLimit":"4.4","upperLimit":"6.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.641","pValueComment":"The comparison was conducted at a 2-sided significance level of 0.05.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.87","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.49","ciUpperLimit":"1.55","estimateComment":"Cox regression model is used for hazard ratio (HR) estimate."}]},{"type":"SECONDARY","title":"Survival Without Clinically Important Grade 3 or 4 Toxicity","description":"Survival without Grade 3 or 4 toxicity is the time from date of randomization to the first date of the following clinically important Grade 3 or 4 TEAEs graded by the Common Terminology Criteria for Adverse Events \\[CTCAE\\], version 3.0: neutropenia (lasting \\>5 days), febrile neutropenia, documented infections related to neutropenia, anemia, thrombocytopenia, fatigue, nausea, vomiting, diarrhea, stomatitis, and neurosensory events; or death due to any cause. Participants who were alive without experiencing Grade 3 or 4 toxicity were censored for this analysis at the date of last contact.","populationDescription":"Analysis was performed on protocol-qualified, intent-to-treat (Q-ITT) population. This population includes all data from all randomized participants, with nonsquamous histology, receiving at least one dose of the study drug according to the treatment the participants were assigned.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"months","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).","groups":[{"id":"OG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"OG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","lowerLimit":"3.0","upperLimit":"8.0"},{"groupId":"OG001","value":"1.3","lowerLimit":"1.1","upperLimit":"1.9"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"The comparison was conducted at a 2-sided significance level of 0.05.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.40","ciUpperLimit":"0.71","estimateComment":"Cox regression model is used for unadjusted hazard ratio (HR) estimate."}]},{"type":"SECONDARY","title":"Survival Without Grade 4 Toxicity","description":"Survival without Grade 4 toxicity is the time from the date of randomization to the first date of a Grade 4 TEAE or death due to any cause. Participants who are alive without experiencing Grade 4 toxicity will be censored for this analysis at the date of last contact.","populationDescription":"Analysis was performed on protocol-qualified, intent-to-treat (Q-ITT) population. This population includes all data from all randomized participants, with nonsquamous histology, receiving at least 1 dose of the study drug according to the treatment the participants were assigned.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"participants","timeFrame":"Baseline to until 218 events (defined as death or Grade 4 toxicity) have been observed (up to 33.3 months).","groups":[{"id":"OG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"OG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.2","lowerLimit":"8.4","upperLimit":"14.9"},{"groupId":"OG001","value":"2.0","lowerLimit":"1.6","upperLimit":"3.8"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"The comparison was conducted at a 2-sided significance level of 0.05.","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.49","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.35","ciUpperLimit":"0.66","estimateComment":"Cox regression model is used for unadjusted hazard ratio (HR) estimate."}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events (AEs)","description":"Summaries of serious AEs (SAEs) and all other non-serious AEs are located in the Reported Adverse Event Module.","populationDescription":"Analysis was performed on safety population. This population includes all participants with non-squamous histology who received at least one dose of study drug. Participants were analysed according to treatments they actually received.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Baseline to until 218 events (defined as death or Grade 3 or 4 toxicity) have been observed (up to 33.3 months).","groups":[{"id":"OG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"},{"id":"OG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"105"}]}],"classes":[{"title":"Non-Serious Adverse Events (AEs)","categories":[{"measurements":[{"groupId":"OG000","value":"94"},{"groupId":"OG001","value":"100"}]}]},{"title":"Serious Adverse Events (SAEs)","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"35"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Pemetrexed Plus Carboplatin","description":"pemetrexed 500 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days","seriousNumAffected":28,"seriousNumAtRisk":106,"otherNumAffected":94,"otherNumAtRisk":106},{"id":"EG001","title":"Docetaxel Plus Carboplatin","description":"docetaxel 75 mg/m\\^2 plus carboplatin AUC 5 mg\\*min/mL on Day 1 every 21 days","seriousNumAffected":35,"seriousNumAtRisk":105,"otherNumAffected":100,"otherNumAtRisk":105}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":10,"numAffected":9,"numAtRisk":105}]},{"term":"Haematotoxicity","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":105}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":105}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":105}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":105}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Cor pulmonale","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":105}]},{"term":"Lower gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":105}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":105}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":105}]},{"term":"Anaphylactic shock","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Bronchopulmonary aspergillosis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":105}]},{"term":"Pneumonia bacterial","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Body temperature increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Troponin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Prostatitis","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Asphyxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Bronchospasm","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":105}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Pleuritic pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":105}]},{"term":"Arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]},{"term":"Superior vena caval occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":106},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":105}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":46,"numAffected":36,"numAtRisk":106},{"groupId":"EG001","numEvents":25,"numAffected":18,"numAtRisk":105}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":80,"numAffected":33,"numAtRisk":106},{"groupId":"EG001","numEvents":139,"numAffected":56,"numAtRisk":105}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":14,"numAtRisk":106},{"groupId":"EG001","numEvents":38,"numAffected":25,"numAtRisk":105}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":109,"numAffected":40,"numAtRisk":106},{"groupId":"EG001","numEvents":203,"numAffected":74,"numAtRisk":105}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":12,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":105}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":105}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":106},{"groupId":"EG001","numEvents":16,"numAffected":13,"numAtRisk":105}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":18,"numAtRisk":106},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":105}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":12,"numAtRisk":106},{"groupId":"EG001","numEvents":43,"numAffected":30,"numAtRisk":105}]},{"term":"Dyspepsia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":106},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":105}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":71,"numAffected":43,"numAtRisk":106},{"groupId":"EG001","numEvents":66,"numAffected":37,"numAtRisk":105}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":9,"numAtRisk":106},{"groupId":"EG001","numEvents":16,"numAffected":11,"numAtRisk":105}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":18,"numAtRisk":106},{"groupId":"EG001","numEvents":31,"numAffected":19,"numAtRisk":105}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":15,"numAtRisk":106},{"groupId":"EG001","numEvents":30,"numAffected":19,"numAtRisk":105}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":105}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":106},{"groupId":"EG001","numEvents":24,"numAffected":21,"numAtRisk":105}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":105}]},{"term":"Oedema","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":105}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":106},{"groupId":"EG001","numEvents":15,"numAffected":7,"numAtRisk":105}]},{"term":"Conjunctivitis infective","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":105}]},{"term":"Nail infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":105}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":9,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":105}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":11,"numAffected":5,"numAtRisk":105}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":105}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":27,"numAtRisk":106},{"groupId":"EG001","numEvents":35,"numAffected":30,"numAtRisk":105}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":106},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":105}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":106},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":105}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":105}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":15,"numAffected":11,"numAtRisk":105}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":105}]},{"term":"Neurotoxicity","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":106},{"groupId":"EG001","numEvents":11,"numAffected":7,"numAtRisk":105}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":106},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":105}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":18,"numAffected":14,"numAtRisk":105}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":105}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":106},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":105}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":106},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":105}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":105}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":106},{"groupId":"EG001","numEvents":46,"numAffected":45,"numAtRisk":105}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":106},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":105}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 13.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":8,"numAtRisk":106},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":105}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"pointOfContact":{"title":"Chief Medical Officer","organization":"Eli Lilly and Company","phone":"800-545-5979"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Venezuela"]},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068437","term":"Pemetrexed"},{"id":"D000077143","term":"Docetaxel"},{"id":"D016190","term":"Carboplatin"}],"ancestors":[{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"},{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"},{"id":"D056831","term":"Coordination Complexes"}]}},"hasResults":true}